ERBB2 and breast cancer: Knowledge of this physiopathology enabled a plethora of trials exploring CDK4/6 inhibitors in monotherapy or in combination with antiendocrine agents in patients diagnosed with metastatic hormone receptor (HR)-positive BC, as well as ongoing clinical trials exploring anti-HER2 therapy in combination with CDK4/6 inhibitors, in HER2-positive disease.